
MALI Platform
AI Stock Research
RTW Investments, LP: latest 13F holdings
For the quarter ending 30 September 2026, RTW Investments, LP reported 83 positions worth $9.9B in total, filed with the SEC on 16 November 2026. The quarter before, it reported $11.7B.
Read the filing at SEC EDGARChecked: the cover page's entry count and total value match the holdings table.
Top 50 positions by value
| # | Issuer | Class | Value | Weight | Shares | vs quarter before |
|---|---|---|---|---|---|---|
| 1 | PROTAGONIST THERAPEUTICS INC | COM | $713.1M | 7.19% | 5,061,175 | Unchanged |
| 2 | ARGENX SE | SPONSORED ADR | $682.3M | 6.88% | 711,584 | Added 0.3% |
| 3 | CG ONCOLOGY INC | COM | $603.6M | 6.08% | 8,514,590 | Unchanged |
| 4 | IRHYTHM HOLDINGS INC | COM | $354.5M | 3.57% | 3,118,913 | Added 42.9% |
| 5 | INSMED INC | COM PAR $.01 | $353.4M | 3.56% | 3,096,545 | Cut 36.1% |
| 6 | TANGO THERAPEUTICS INC | COM | $350.5M | 3.53% | 14,048,477 | Added 1.1% |
| 7 | ERASCA INC | COM | $329.1M | 3.32% | 22,446,754 | Added 25.1% |
| 8 | SPYRE THERAPEUTICS INC | COM NEW | $328.7M | 3.31% | 3,691,791 | Cut 13.2% |
| 9 | RADNET INC | COM | $319.2M | 3.22% | 4,630,697 | Cut 4.5% |
| 10 | TARSUS PHARMACEUTICALS INC | COM | $273.9M | 2.76% | 3,484,066 | Added 3.8% |
| 11 | ZAI LAB LTD | ADR | $272.6M | 2.75% | 10,350,973 | Added 57.5% |
| 12 | REPLIGEN CORP | COM | $266.3M | 2.68% | 1,385,398 | Added 11.7% |
| 13 | GUARDANT HEALTH INC | COM | $264.2M | 2.66% | 1,481,033 | Unchanged |
| 14 | CELCUITY INC | COM | $262.8M | 2.65% | 3,304,903 | Unchanged |
| 15 | ORUKA THERAPEUTICS INC | COM | $261.4M | 2.64% | 3,139,030 | Unchanged |
| 16 | NATERA INC | COM | $248.0M | 2.50% | 600,000 | Cut 40.0% |
| 17 | CYTOKINETICS INC | COM NEW | $188.6M | 1.90% | 2,862,003 | Unchanged |
| 18 | UROGEN PHARMA LTD | COM | $184.6M | 1.86% | 4,543,895 | Unchanged |
| 19 | ESTABLISHMENT LABS HLDGS INC | COM | $171.1M | 1.72% | 2,665,695 | Added 0.4% |
| 20 | XENCOR INC | COM | $170.3M | 1.72% | 6,827,461 | Added 0.7% |
| 21 | MADRIGAL PHARMACEUTICALS INC | COM | $157.6M | 1.59% | 312,817 | Cut 84.3% |
| 22 | IMMUNOCORE HLDGS PLC | ADS | $147.5M | 1.49% | 4,869,798 | Unchanged |
| 23 | STOKE THERAPEUTICS INC | COM | $146.2M | 1.47% | 5,623,525 | Unchanged |
| 24 | ACADIA PHARMACEUTICALS INC | COM | $144.0M | 1.45% | 7,144,524 | Unchanged |
| 25 | KODIAK SCIENCES INC | COM | $141.1M | 1.42% | 1,487,934 | Unchanged |
| 26 | GH RESEARCH PLC | ORDINARY SHARES | $139.3M | 1.40% | 5,933,815 | Unchanged |
| 27 | COMPASS PATHWAYS PLC | SPONSORED ADS | $136.2M | 1.37% | 10,948,591 | Added 2.3% |
| 28 | NEUROCRINE BIOSCIENCES INC | COM | $133.7M | 1.35% | 942,684 | Cut 25.7% |
| 29 | ULTRAGENYX PHARMACEUTICAL IN | COM | $128.2M | 1.29% | 8,529,394 | Added 9.4% |
| 30 | KAILERA THERAPEUTICS INC | COMMON STOCK | $123.1M | 1.24% | 10,776,820 | Unchanged |
| 31 | BELITE BIO INC | SPONSORED ADS | $121.5M | 1.22% | 715,332 | Unchanged |
| 32 | IMMATICS N.V | SHS | $118.7M | 1.20% | 13,521,551 | Added 4.4% |
| 33 | REPLIMUNE GROUP INC | COM | $112.4M | 1.13% | 8,491,525 | Added 14.6% |
| 34 | IMMUNOVANT INC | COM | $107.3M | 1.08% | 3,177,849 | Unchanged |
| 35 | PTC THERAPEUTICS INC | COM | $104.7M | 1.06% | 1,615,819 | Cut 79.1% |
| 36 | VIRIDIAN THERAPEUTICS INC | COM | $101.1M | 1.02% | 4,910,126 | New |
| 37 | CASTLE BIOSCIENCES INC | COM | $98.7M | 0.99% | 2,778,335 | Unchanged |
| 38 | UNIQURE NV | SHS | $95.2M | 0.96% | 3,941,572 | Unchanged |
| 39 | COGENT BIOSCIENCES INC | COM | $73.9M | 0.75% | 2,309,021 | Unchanged |
| 40 | STRUCTURE THERAPEUTICS INC | SPONSORED ADS | $71.4M | 0.72% | 2,282,138 | Added 42.0% |
| 41 | AXOGEN INC | COM | $69.6M | 0.70% | 1,659,376 | Added 64.0% |
| 42 | TAYSHA GENE THERAPIES INC | COM SHS | $66.0M | 0.67% | 13,560,258 | Unchanged |
| 43 | ORCHESTRA BIOMED HLDGS INC | COM | $59.4M | 0.60% | 9,556,063 | Unchanged |
| 44 | VERASTEM INC | COM NEW | $54.1M | 0.55% | 6,718,081 | Added 1.2% |
| 45 | DANAHER CORP DEL | COM | $51.0M | 0.51% | 230,000 | Unchanged |
| 46 | HINGE HEALTH INC | CL A | $48.6M | 0.49% | 500,000 | Unchanged |
| 47 | ROCKET PHARMACEUTICALS INC | COM | $46.5M | 0.47% | 17,687,772 | Unchanged |
| 48 | SOLID BIOSCIENCES INC | COM NEW | $42.7M | 0.43% | 5,905,426 | Added 51.7% |
| 49 | NEUROGENE INC | COM | $42.1M | 0.42% | 1,512,456 | Added 11.0% |
| 50 | CULLINAN THERAPEUTICS INC | COM | $36.3M | 0.37% | 2,364,347 | Unchanged |
Showing the largest 50 of 83 positions. Every position is in MALI's SEC Financials & 13F workspace.
New this quarter
- VIRIDIAN THERAPEUTICS INC · $101.1M
Sold out
- ALKERMES PLC · was $87.6M
- DEFINIUM THERAPEUTICS INC · was $18.8M
- IDEAYA BIOSCIENCES INC · was $13.8M
- ATAIBECKLEY INC · was $10.5M
- TENAX THERAPEUTICS INC · was $10.1M
- PERCEPTIVE CAP SOLUTIONS COR · was $8.1M
- WAVE LIFE SCIENCES LTD · was $7.8M
- 4D MOLECULAR THERAPEUTICS IN · was $6.3M
- MAZE THERAPEUTICS INC · was $6.3M
- AVALO THERAPEUTICS INC · was $3.2M
Reading a 13F
A 13F lists a manager's long positions in US-listed securities at the end of a quarter, filed up to 45 days later. It leaves out short positions, cash and most non-US holdings, so it is a partial, delayed view of a portfolio. Nothing here is investment advice.
Positions are named as the manager filed them. Values are the filing's own, in US dollars; changes compare share counts with the quarter before.